Next Article in Journal
MrHex1 is Required for Woronin Body Formation, Fungal Development and Virulence in Metarhizium robertsii
Next Article in Special Issue
Examining the Impacts of CO2 Concentration and Genetic Compatibility on Perennial Ryegrass—Epichloë festucae var lolii Interactions
Previous Article in Journal
Interplay between Fungal Infection and Bacterial Associates in the Wax Moth Galleria mellonella under Different Temperature Conditions
Article

Genome-Scale Metabolic Model of the Human Pathogen Candida albicans: A Promising Platform for Drug Target Prediction

1
Department of Bioengineering, Instituto Superior Técnico, Universidade de Lisboa, 1049-001 Lisbon, Portugal
2
Institute for Bioengineering and Biosciences, Biological Sciences Research Group, Instituto Superior Técnico, 1049-001 Lisbon, Portugal
3
Centre of Biological Engineering, Universidade do Minho, 4710-057 Braga, Portugal
4
Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa (ITQB-NOVA), 2780-157 Oeiras, Portugal
*
Authors to whom correspondence should be addressed.
J. Fungi 2020, 6(3), 171; https://doi.org/10.3390/jof6030171
Received: 27 July 2020 / Revised: 3 September 2020 / Accepted: 8 September 2020 / Published: 11 September 2020
(This article belongs to the Special Issue Systems Biology in Fungal Research)
Candida albicans is one of the most impactful fungal pathogens and the most common cause of invasive candidiasis, which is associated with very high mortality rates. With the rise in the frequency of multidrug-resistant clinical isolates, the identification of new drug targets and new drugs is crucial in overcoming the increase in therapeutic failure. In this study, the first validated genome-scale metabolic model for Candida albicans, iRV781, is presented. The model consists of 1221 reactions, 926 metabolites, 781 genes, and four compartments. This model was reconstructed using the open-source software tool merlin 4.0.2. It is provided in the well-established systems biology markup language (SBML) format, thus, being usable in most metabolic engineering platforms, such as OptFlux or COBRA. The model was validated, proving accurate when predicting the capability of utilizing different carbon and nitrogen sources when compared to experimental data. Finally, this genome-scale metabolic reconstruction was tested as a platform for the identification of drug targets, through the comparison between known drug targets and the prediction of gene essentiality in conditions mimicking the human host. Altogether, this model provides a promising platform for global elucidation of the metabolic potential of C. albicans, possibly guiding the identification of new drug targets to tackle human candidiasis. View Full-Text
Keywords: Candida albicans; global stoichiometric model; drug targets; metabolic reconstruction; gene essentiality Candida albicans; global stoichiometric model; drug targets; metabolic reconstruction; gene essentiality
Show Figures

Figure 1

MDPI and ACS Style

Viana, R.; Dias, O.; Lagoa, D.; Galocha, M.; Rocha, I.; Teixeira, M.C. Genome-Scale Metabolic Model of the Human Pathogen Candida albicans: A Promising Platform for Drug Target Prediction. J. Fungi 2020, 6, 171. https://doi.org/10.3390/jof6030171

AMA Style

Viana R, Dias O, Lagoa D, Galocha M, Rocha I, Teixeira MC. Genome-Scale Metabolic Model of the Human Pathogen Candida albicans: A Promising Platform for Drug Target Prediction. Journal of Fungi. 2020; 6(3):171. https://doi.org/10.3390/jof6030171

Chicago/Turabian Style

Viana, Romeu, Oscar Dias, Davide Lagoa, Mónica Galocha, Isabel Rocha, and Miguel C. Teixeira. 2020. "Genome-Scale Metabolic Model of the Human Pathogen Candida albicans: A Promising Platform for Drug Target Prediction" Journal of Fungi 6, no. 3: 171. https://doi.org/10.3390/jof6030171

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop